News
TRANSCAN-3 JOINT TRANSNATIONAL CALL 2022
on:
"Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy"
is open for submission
Please visit the TRANSCAN-3 website at
https://transcan.eu/funding/calls/joint-call-jtc-2022-.kl
Other news (outside TRANSCAN):
The Digital Institute for Cancer Outcomes Research (DIGICORE), a 30-strong network of cancer centres established as an EU European Economic Interest Group, is delighted to announce an innovative new training programme for early career researchers in oncology.
IDEAL4RWE is a new training program to equip early-career researchers (<45 years old) with the technical and leadership skills to build collaborative teams for oncology RWE research.
Please register for an introductory webinar on the 19th April 2022 (https://lnkd.in/ez7y4kWU).
Brochure for more details: https://tinyurl.com/y7aurdtk
International Networking Event (virtual)
was held on 22 April 2021 hrs 9:00 CET
focussed on the co-funded Joint Transnational Call for proposals, JTC2021, on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"
event organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3
The 3rd and final TRANSCAN-2 symposium on Tumour Heterogeneity was held in Milan on October 24th, 2019
The symposium included talks from the funded consortia of JTC2014 co-funded by the EU, an exciting discussion on the impact and added value of transnational collaborations on cancer research and a poster prize competition for young scientists.
The event was hosted by Regione Lombardia, Italy, with the collaboration of Fondazione Regionale per la Ricerca Biomedica
Abstract book
For further information please contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
JTC 2017 on: Translational research on rare cancers
12 projects selected for funding, visit the page
JTC 2016 on: Minimally and non-invasive methods for early detection and/or progression of cancer.
14 projects selected for funding
JTC 2015 on: Immunology and immunotherapy of cancer: strengthening the translational aspects.
7 projects selected for funding
JTC 2014 on: Translational research on human tumour heterogeneity to overcome recurrence and resistance to therapy.
